RxDoctor Payments Data

Rona Manneh, MD

Internal Medicine · Indianapolis, INNPI 1548432511

Payments from drug & device makers

$1,368in general payments, 2019–2025

Across 76 payments — averaging $18.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$247
  • Novo Nordisk$239
  • Astellas Pharma US Inc$181
  • Lilly USA, LLC$176
  • Exact Sciences$158
  • AstraZeneca$114
  • plus $253 from 10 others

What the payments were for

  • Food & beverage$1,368100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,368 in reported general payments places this provider in the 75th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$105,475
Medicare patients
147
Services billed
2,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$69,117
MounjaroTirzepatide42$57,519
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$41,196
TrulicityDulaglutide17$30,520
XareltoRivaroxaban17$18,894
JanuviaSitagliptin Phosphate25$17,865
JardianceEmpagliflozin14$14,269
AbrysvoRsv Vacc, Pref A And Pref B/Pf42$13,223
ShingrixVaricella-Zoster Ge/As01b/Pf25$5,510
Varenicline Tartrate12$3,002
Testosterone13$2,540
Rosuvastatin Calcium225$2,189
Levothyroxine Sodium190$2,175
Atorvastatin Calcium204$1,895
Albuterol Sulfate HfaAlbuterol Sulfate50$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$176$88,03959 claims
Novo NordiskOzempic$239$69,11772 claims
GSKTrelegy Ellipta, Shingrix$45$46,70651 claims
MerckJanuvia$12$17,86525 claims
Boehringer IngelheimJardiance$19$14,26914 claims
PfizerAbrysvo$34$13,22342 claims
AbbVieSynthroid$17$1,03116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →